Drug news
Abilify Depot is filed in EU for maintenance therapy of Schizophrenia
The European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for a once-monthly intramuscular depot formulation of Abilify (aripiprazole) from Otsuka Pharma and Lundbeck.
The companies are seeking approval of the long-acting formulation of the dopamine D2 partial agonist as a maintenance therapy for adults with Schizophrenia.